2026-06-29T02:50:08Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/720902023-08-28T07:36:56Zcom_20.500.14352_14col_20.500.14352_15

CRISPR/Cas9 in Chronic Lymphocytic Leukemia Hernández Sánchez, María leukemia CRISPR/Cas9 editing Oncología Genética Bioquímica (Farmacia) 3201.01 Oncología 2409 Genética Genome-editing systems such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology have uncovered new opportunities to model diseases such as chronic lymphocytic leukemia. CRISPR/Cas9 is an important means of advancing functional studies of Chronic Lymphocytic Leukemia (CLL) through the incorporation, elimination and modification of somatic mutations in CLL models. Instituto de Salud Carlos III (ISCIII)/ FEDER Sección Deptal. de Bioquímica y Biología Molecular (Farmacia) Fac. de Farmacia TRUE pub 2023-06-22T11:05:17Z 2023-06-22T11:05:17Z 2022-05-27 journal article https://hdl.handle.net/20.500.14352/72090 2673-8392 10.3390/encyclopedia2020061 eng CD19/00222 Atribución 3.0 España https://creativecommons.org/licenses/by/3.0/es/ open access application/pdf MPDI